1-4 of 4
Motalib Smahi
Close
Sort by
Journal Articles

Lack of Inter-Laboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa Activity and the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time

Pierre Toulon, MD, Motalib Smahi, MD, Neila De Pooter, MD, Elamine Zereg
Journal: Blood
Blood (2017) 130 (Supplement 1): 3357.
https://doi.org/10.1182/blood.V130.Suppl_1.3357.3357
Published: 2017
Journal Articles

Age-Adjusted D-Dimer Cut-Off Levels to Rule-out Venous Thromboembolism in Patients with Non-High Pre-Test Probability. Clinical Performance and Cost-Effectiveness Analysis

Pierre A. Toulon, MD PhD, Neila De Pooter, MD, Marie Brionne-François, MD, Motalib Smahi, MD, Lien Abecassis, MD
Journal: Blood
Blood (2016) 128 (22): 4729.
https://doi.org/10.1182/blood.V128.22.4729.4729
Published: 2016
Journal Articles

Detection of Mild Clotting Factor Deficiencies. Critical Role of the Activated Partial Thromboplastin Time (aPTT) Reagent

Pierre A. Toulon, Yaelle Eloit, Motalib Smahi, Didier Jambou, Anny Appert-Flory, Florence Fischer
Journal: Blood
Blood (2015) 126 (23): 3281.
https://doi.org/10.1182/blood.V126.23.3281.3281
Published: 2015
Journal Articles

Monitoring Treatments with Unfractionated Heparin: CTAD Must Be Used Instead of Citrate as the Anticoagulant Solution When Using Partial-Draw Collection Tubes.

Pierre A. Toulon, MD, PhD, Lién Abecassis, MD, Motalib Smahi, MD, Catherine Ternisien, MD
Journal: Blood
Blood (2009) 114 (22): 2091.
https://doi.org/10.1182/blood.V114.22.2091.2091
Published: 2009